FDA Approves Aurinia Pharma's Lupkynis - Second Lupus Nephritis Drug In A Month
India, Jan. 23 -- The FDA has approved Aurinia Pharmaceuticals Inc.'s (AUPH) LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis.
LUPKYNIS, generically known as voclosporin, becomes the second FDA-approved therapy for lupus nephritis, with the first being GlaxoSmithKline plc's (GSK) BENLYSTA, which was approved as recently as last month.
Aurinia's LUPKYNIS is administered orally while BENLYSTA is administered intravenously (IV) or subcutaneously.
The global peak sales of LUPKYNIS are estimated to be in excess of $1 billion, according to the company.
Lupus nephritis is an inflammation of the kidney caused by Systemic Lupus Erythematosus - resulting in irreversi...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.